Avanos Medical, Inc.
AVNS
$24.96
-$0.01-0.02%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.87% | 1.95% | 2.70% | 1.48% | 1.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.87% | 1.95% | 2.70% | 1.48% | 1.34% |
| Cost of Revenue | 14.29% | 13.31% | 10.16% | 6.04% | 5.35% |
| Gross Profit | -4.78% | -7.19% | -3.28% | -2.13% | -1.77% |
| SG&A Expenses | 0.77% | -1.66% | 2.26% | 1.52% | -2.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 5.88% | -73.68% | 66.67% | -62.79% | 47.83% |
| Total Operating Expenses | 7.37% | 4.85% | 5.66% | 2.99% | 0.91% |
| Operating Income | -56.50% | -54.14% | -44.42% | -20.98% | 9.28% |
| Income Before Tax | 82.71% | 83.59% | -1,969.35% | -3,508.57% | -14,733.33% |
| Income Tax Expenses | 140.94% | 139.41% | -538.64% | -327.14% | -446.51% |
| Earnings from Continuing Operations | 80.43% | 81.13% | -2,259.45% | -6,690.00% | -23,662.50% |
| Earnings from Discontinued Operations | -- | -- | 95.00% | -371.43% | 92.74% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.66% | 81.41% | -3,086.62% | -6,115.58% | -518.33% |
| EBIT | -56.50% | -54.14% | -44.42% | -20.98% | 9.28% |
| EBITDA | -31.33% | -31.40% | -27.49% | -10.76% | 5.30% |
| EPS Basic | 80.78% | 81.54% | -3,090.51% | -6,091.07% | -530.36% |
| Normalized Basic EPS | -66.21% | -59.34% | -48.01% | -19.38% | 42.97% |
| EPS Diluted | 80.80% | 81.51% | -3,197.02% | -6,306.59% | -530.44% |
| Normalized Diluted EPS | -66.44% | -59.51% | -47.87% | -19.65% | 42.57% |
| Average Basic Shares Outstanding | 0.87% | 0.60% | 0.27% | -0.38% | -1.08% |
| Average Diluted Shares Outstanding | 0.48% | 0.16% | -0.38% | -0.38% | -0.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |